Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection

Journal of Infectious Diseases

Volumn 191, Issue 10, 2005, Pages 1680-1685

  García, Felipe ^a,c   Lejeune, Merylene ^a   Climent, Nuria ^a   Gil, Cristina ^a   Alcamí, José ^b   Morente, Vanessa ^a   Alós, Llucia ^a   Ruiz, Alba ^a   Setoain, Javier ^a   Fumero, Emilio ^a   Castro, Pedro ^a   López, Anna ^a   Cruceta, Anna ^a   Piera, Carlos ^a   Florence, Eric ^a   Pereira, Arturo ^a   Libois, Agnes ^a   González, Nuria ^b   Guilá, Meritxell ^a   Caballero, Miguel ^a   Lomeña, Francisco ^a   Joseph, Joan ^a   Miró, José M ^a   Pumarola, Tomás ^a   Plana, Montserrat ^a   Gatell, José M ^a   Gallart, Teresa ^a   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DENDRITIC CELL VACCINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD;

AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; VACCINES, INACTIVATED; VIRAL LOAD;

EID: 20844456226     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/429340     Document Type: Article

References (15)

1. Chougnet C, Cohen SS, Kawamura T, et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. J Immunol 1999; 163:1666-73.
2. Sapp M, Engelmayer J, Larsson M, Granelli-Piperno A, Steinman R, Bhardwaj N. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol Lett 1999; 66:121-8.
3. + T-cell responses from chronically infected individuals. J Virol 2001; 75:2142-53.
4. Kundu SK, Engleman E, Benike C, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998; 14:551-60.
5. Lu W, Arraes L, Ferreira W, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359-65.
6. Garcia F, Knobel H, Sambeat MA, et al. An open randomized study comparing d4T plus ddI and nevirapine (QD) vs d4T plus ddI and nevirapine (BID) in antiretroviral naive chronic HIV-1 infected patients in very early stages. Spanish SCAN Study. AIDS 2000; 14:2485-94.
7. 3. J Acquir Immune Defic Syndr 2004; 36:791-9.
8. García F, Plana M, Arnedo M, et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS 2003; 17:43-51.
9. Alós L, Navarrete P, Morente V, et al. Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. Mod Pathol 2005; 18:127-36.
10. Phan G, Touloukian C, Yang J, et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 2003; 26:349-56.
11. + regulatory T cells in vivo in humans. Blood 2002; 100:174-7.
12. + T cells. J Exp Med 2004; 200:701-12.
13. + T lymphocytes. Nature 2003; 421:852-6.
14. Brodie SJ, Patterson BK, Lewinsohn DA, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest 2000; 105:1407-17.
15. + T cell responses induced by dendritic cells generated in the presence of IFN-alpha. J Immunol 2004; 172:7832-40.